Both in Pharmaceuticals
Akebia Therapeutics vs Upstream Bio
Over the past year AKBA returned −66.8% and UPB returned −85.2%; their daily moves had a correlation of 0.21.
AKBA −66.8% UPB −85.2%Growth of $1, one year, split-adjusted
| Metric | AKBA | UPB |
|---|---|---|
| Price | $0.6947 | $3.70 |
| Market cap | $192.5M | $202.7M |
| Today | −4.28% | +9.14% |
| 1 month | −20.9% | −19.4% |
| 6 months | −53.1% | −59.7% |
| Year to date | −56.9% | −86.4% |
| 1 year | −67.2% | −85.2% |
| Revenue growth (YoY) | −21.4% | −17.5% |
| Gross margin | 78.8% | 100.0% |
| Net margin | −18.1% | −5136.1% |
| P/E (TTM) | — | — |
| Price / sales | 0.9× | 64.2× |
| Net cash | $106.0M | $261.3M |
| Dividend yield | — | — |
| Volatility (60d) | 72.3% | 84.2% |
| Short % of float | 8.7% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).